DiaMedica Therapeutics (DMAC) CMO receives 67,500 stock options expiring 2036

Rhea-AI Filing Summary

DiaMedica Therapeutics Inc. reported that its Chief Medical Officer, Julie Krop, received a new stock option grant. The award covers 67,500 stock options with an exercise price of $5.84 per share and expires on June 1, 2036.

The options relate to 67,500 voting common shares and were granted at no upfront cost as a compensation award. According to the vesting terms, 25% of the options are scheduled to vest on the one-year anniversary of the grant date, with the remaining options vesting in twelve equal quarterly installments thereafter.

Insights

Equity Compensation Analyst

Routine stock option grant to the CMO as part of equity compensation.

The filing shows Chief Medical Officer Julie Krop receiving 67,500 stock options with an exercise price of $5.84 per share, expiring on June 1, 2036. This is coded as a grant or award, not an open-market purchase or sale.

The vesting structure is standard for executive incentives, with 25% vesting after one year and the remainder in twelve quarterly installments. This design encourages long-term retention and alignment with shareholder value, but actual economic benefit will depend on DiaMedica Therapeutics’ future share price performance.

Insider Trade Summary

1 transaction reported

Mixed 1 txn

Insider Krop Julie

Role Chief Medical Officer

Type	Security	Shares	Price	Value
Grant/Award	Stock Option (right to buy)	67,500	$0.00	--

Holdings After Transaction: Stock Option (right to buy) — 67,500 shares (Direct, null)

Footnotes (1)

1. [object Object]

Key Figures

Stock options granted: 67,500 options Exercise price: $5.84 per share Expiration date: June 1, 2036 +2 more

5 metrics

Stock options granted 67,500 options Grant of stock options to Chief Medical Officer

Exercise price $5.84 per share Stock option strike price

Expiration date June 1, 2036 Option expiration

Shares underlying options 67,500 voting common shares Underlying security for options

Post-transaction derivative holdings 67,500 options Total derivative securities following transaction

Key Terms

Stock Option (right to buy), exercise price, vesting, grant, award, or other acquisition, +1 more

5 terms

Stock Option (right to buy) financial

"security_title: "Stock Option (right to buy)""

exercise price financial

"conversion_or_exercise_price: "5.8400""

The exercise price is the fixed amount at which you can buy or sell an asset, like a stock, when using an options contract. It matters because it helps determine whether exercising the option will be profitable or not, depending on the current market price. Think of it as the set price you agree on today to buy or sell later.

vesting financial

"Scheduled to vest with respect to 25% of the shares on the one-year anniversary"

Vesting is the process by which you earn full ownership of something, like company stock or a retirement benefit, over time. It’s like earning the right to keep a gift piece by piece the longer you stay with a company, making sure employees stay committed before they receive all the benefits.

grant, award, or other acquisition financial

"transaction_code_description: "Grant, award, or other acquisition""

Voting Common Shares financial

"underlying_security_title: "Voting Common Shares""

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Form 4 Insider Transactions: What Each Field Means →

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Krop Julie

(Last) (First) (Middle)

301 CARLSON PARKWAY

SUITE 210

(Street)

MINNEAPOLIS MINNESOTA 55305

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
DiaMedica Therapeutics Inc. [ DMAC ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	Chief Medical Officer

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
06/01/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Stock Option (right to buy)	$5.84	06/01/2026		A		67,500		(1)	06/01/2036	Voting Common Shares	67,500	$0	67,500	D

Explanation of Responses:

1. Scheduled to vest with respect to 25% of the shares on the one-year anniversary of the grant date, with the remaining shares scheduled to vest in twelve equivalent quarterly installments.

	/s/ Joshua L. Colburn, attorney-in-fact	06/03/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)

FAQ

What did DiaMedica Therapeutics (DMAC) disclose in this Form 4 for Julie Krop?

DiaMedica Therapeutics disclosed that Chief Medical Officer Julie Krop received a grant of 67,500 stock options. These options are a compensation award, not an open-market trade, and give her the right to buy voting common shares at a fixed exercise price.

What are the key terms of Julie Krop’s stock option grant at DiaMedica Therapeutics (DMAC)?

The grant covers 67,500 stock options with an exercise price of $5.84 per share and an expiration date of June 1, 2036. Each option relates to one voting common share of DiaMedica Therapeutics, providing potential future ownership if exercised.

How do Julie Krop’s DiaMedica (DMAC) stock options vest over time?

The options are scheduled to vest with respect to 25% of the shares on the one-year anniversary of the grant date. The remaining 75% are set to vest in twelve equivalent quarterly installments, creating a multi-year vesting schedule tied to continued service.

Does the Form 4 for DiaMedica (DMAC) show Julie Krop buying or selling shares in the market?

No, the Form 4 shows a grant of stock options coded as a grant or award acquisition, not a market transaction. There are no open-market purchases or sales reported; the transaction reflects equity compensation rather than trading activity.

How many DiaMedica (DMAC) derivative securities does Julie Krop hold after this transaction?

Following the transaction, Julie Krop is shown holding 67,500 derivative securities related to stock options. These options give her the right to acquire the same number of DiaMedica voting common shares at the specified exercise price, subject to the vesting schedule and expiration date.

What role does Julie Krop hold at DiaMedica Therapeutics (DMAC) in this Form 4?

Julie Krop is identified as the Chief Medical Officer of DiaMedica Therapeutics. The stock option grant reported in the Form 4 appears as part of her executive equity compensation, aligning her potential future rewards with the company’s long-term share performance.